Introduction {#s1}
============

Lithium was initially reported for treatment as a mood stabilizer over 60 years ago ([@bib8]) and is still widely used for the treatment of Bipolar Disorder ([@bib47]; [@bib55]; [@bib71]). However, despite its extensive use for the treatment of bipolar disorder, the cellular and molecular mechanisms underlying its antimanic and antidepressant responses remain poorly understood ([@bib10]; [@bib43]). Putative mechanisms for the therapeutic effects of lithium include inhibition of glycogen synthase kinase-3β (GSK3β) ([@bib36]), upregulation of neurotrophins, as well as their receptors, and downregulation of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) expression ([@bib4]; [@bib16], [@bib17]; [@bib29]; [@bib63]; [@bib72]) among others. However, which ---if any--- of these effects of lithium are the primary mechanism for treatment for bipolar disorder is currently unknown.

Earlier studies suggested a potential link between the action of lithium as a mood stabilizer and neurotrophins, in particular brain-derived neurotrophic factor (BDNF). BDNF and aberrant signaling through its high affinity receptor tropomyosin receptor kinase B (TrkB) have been proposed to underlie both the pathophysiology and treatment of bipolar disorder ([@bib7]; [@bib44]; [@bib62]). Previous work has shown that patients with bipolar disorder have decreased peripheral BDNF mRNA in blood lymphocytes and monocytes in comparison to healthy controls ([@bib12]). Moreover, both manic and depressive states in patients with bipolar disorder have been associated with significantly decreased BDNF blood serum levels compared to patients in euthymic states and healthy controls ([@bib22]; [@bib69]). Post-mortem analysis of hippocampal tissue has also revealed reduced BDNF protein levels in patients with bipolar disorder ([@bib37]). In rodents, experimental interventions that cause manic-like ([@bib24]; [@bib25]; [@bib34]) and depressive-like behaviors ([@bib64]; [@bib68]; [@bib70]) have also been shown to result in decreased BDNF mRNA and protein levels in the hippocampus. In contrast, lithium treatment is associated with increased BDNF protein levels in the serum of patients with bipolar disorder ([@bib11]; [@bib13]; [@bib67]). In rodent models, chronic lithium treatment has been shown to increase BDNF mRNA and protein expression in hippocampus, cortex, and amygdala as well as cortical neurons in culture ([@bib26]; [@bib34]; [@bib73]). Lithium treatment has also been shown to increase TrkB activity in neuronal cultures suggesting an increase in BDNF-TrkB signaling ([@bib31]).

While previous work has demonstrated that BDNF is necessary for the antidepressant response of conventional antidepressants ([@bib1]; [@bib32]; [@bib48], [@bib49]), as well as the rapid antidepressant effects of ketamine ([@bib6]; [@bib39]), it is currently unknown whether BDNF or the TrkB receptor are required for lithium's antidepressant or antimanic effects. In this study, we establish the necessity of BDNF-TrkB signaling in the antimanic-like but not antidepressant-like response to lithium. We also identify a direct effect of lithium treatment on AMPAR trafficking, where AMPA receptor surface expression is decreased due to a sustained increase in dynamin mediated AMPAR endocytosis. This process is dependent on BDNF-TrkB function and results in synaptic downscaling where unitary postsynaptic responses are decreased in a manner proportional to their relative strengths. Collectively, our findings reveal a requirement for neurotrophic signaling in the behavioral and cellular effects of lithium. These data provide novel mechanistic insight into the action of lithium which may underlie its therapeutic effect for the treatment of bipolar disorder.

Results {#s2}
=======

Chronic lithium treatment increases BDNF expression {#s2-1}
---------------------------------------------------

Previous studies have used mice to examine the impact of lithium treatment on molecular signaling. However, typically the lithium serum concentration is not determined in mice following lithium treatment leaving it unclear whether reported changes occur within the therapeutic range. We established a lithium protocol in which C57BL/6 mice were given 0.2% lithium chloride (LiCl) chow for four days, followed by 0.4% LiCl chow for the remainder of the treatment and testing period, which lasted a total of 11--17 days depending on the experiment ([Figure 1A](#fig1){ref-type="fig"}). This protocol resulted in a lithium serum concentration in treated mice that was within the therapeutic range of 0.5--2 mM ([@bib3]), with an average concentration of 1 mM ([Figure 1B](#fig1){ref-type="fig"}). Control (CTL) mice were given the same chow without lithium. Following 11 days of lithium treatment, mice were sacrificed and the hippocampus rapidly removed. To confirm our lithium protocol produced the expected molecular effects, we examined GSK3 inhibition ([@bib36]; [@bib65]), by measuring the phosphorylation of GSK3β at serine nine with western blot analysis and found a significant increase relative to total GSK3β ([Figure 1C](#fig1){ref-type="fig"}). We next examined whether the lithium treatment regulated the expression of BDNF in the hippocampus. Using Q-PCR targeted to the coding exon of *Bdnf*, we found lithium treated mice had a significant increase in *Bdnf* mRNA expression ([Figure 1D](#fig1){ref-type="fig"}). We also found a significant increase in BDNF protein expression ([Figure 1E](#fig1){ref-type="fig"}) in lithium treated mice relative to CTL mice.10.7554/eLife.25480.003Figure 1.Lithium serum concentration within the therapeutic range increases BDNF expression in mice.(**A**) Timeline of chronic lithium chloride (LiCl) treatment and behavioral testing. (**B**) (Left) Example standard curve of lithium counts used to calculate lithium concentration in blood serum. (Right). Average lithium concentration in blood serum in control and treated mice (*n*= 9--12 per group). (**C**) Chronic lithium treatment in mice produces a significant decrease in immobility in the FST compared to the control group (Student's unpaired *t* test \*p\<0.0001, *n* = 10 mice per group). (**D**) Chronic lithium treatment caused a significant increase in *Bdnf* mRNA expression in the hippocampus (Student's unpaired *t* test \*p=0.04, *n* = 8--9 mice per group). (**E**) Chronic lithium treatment caused a significant increase in BDNF protein expression in the hippocampus (Student's unpaired *t* test \*p=0.002, *n* = 10 mice per group).**DOI:** [http://dx.doi.org/10.7554/eLife.25480.003](10.7554/eLife.25480.003)

BDNF is required for the antimanic-like effect of lithium {#s2-2}
---------------------------------------------------------

Since lithium increases the expression of BDNF mRNA and protein levels, we investigated whether BDNF was necessary for lithium's behavioral action. Inducible *Bdnf* KO mice, in which *Bdnf* is deleted \~70--80% in broad forebrain regions ([@bib48]), were given lithium treated chow following our protocol ([Figure 1A](#fig1){ref-type="fig"}). To determine whether this lithium treatment produced the expected behavioral effects, we tested mice in the forced swim test (FST), a test with predictive value for antidepressant responses ([@bib56]). Littermate control (CTL) mice treated with lithium showed a significant reduction in immobility time that was suggestive of an antidepressant-like response compared to CTL mice that did not receive lithium ([Figure 2A](#fig2){ref-type="fig"}). In agreement with previous data we found that loss of *Bdnf* in the inducible *Bdnf* KO mice did not alter immobility in the FST compared to CTL mice ([@bib48]). We also found that *Bdnf* KO mice administered lithium showed a significant reduction in immobility comparable to KO mice that did not receive lithium ([Figure 2A](#fig2){ref-type="fig"}) suggesting that BDNF is not necessary for the antidepressant-like effect of lithium in the FST.10.7554/eLife.25480.004Figure 2.BDNF expression is required for the antimanic-like effect of lithium.(**A**) Chronic lithium treatment caused a significant decrease in the immobility time in the FST in littermate CTL and inducible *Bdnf* KO mice in comparison to vehicle chow treated mice (ANOVA F~3,90~ = 18.1 \*p\<0.0001, Dunnett's multiple comparisons Veh CTL vs LiCl CTL \*p\<0.0001, Veh *Bdnf* KO vs LiCl *Bdnf* KO \*p\<0.0001, *n* = 19--28 mice per group). (**B**) Acute amphetamine injection caused a significant increase in locomotor activity in control and *Bdnf* KO mice in comparison to the saline injected mice. Lithium treatment resulted in a nonsignificant increase in locomotor activity of CTL and *Bdnf* KO mice compared to vehicle treated mice. Chronic lithium treatment blunted the increased locomotor activity following acute amphetamine injection in the CTL littermate mice, but not in the *Bdnf* KO mice (ANOVA F~7,98~ = 12.75 p\<0.0001, Tukey's multiple comparisons CTL Veh-Sal vs CTL Veh-Amph \*p\<0.0001, CTL LiCl-Sal vs CTL LiCl-Amph p*=*0.97, CTL Veh-Sal vs CTL LiCl-Sal p*=*0.23, *Bdnf* KO Veh-Sal vs *Bdnf* KO Veh-Amph \*p\<0.0001, *Bdnf* KO LiCl-Sal vs *Bdnf* KO LiCl-Amph \*p=0.01, *Bdnf* KO Veh-Sal vs *Bdnf* KO LiCl-Sal p=0.44, *n* = 11--15 mice per group). (**C**) Chronic lithium treatment resulted in a 20% reduction in the I/O curve in the CTL mice chronically treated with LiCl chow in comparison to Veh CTL mice, which is plotted as the slope of the fEPSP is plotted as a function of the presynaptic fiber volley. Linear fit slopes were calculated for Veh CTL(5.53 ± 0.2) vs CTL LiCl (4.656 ± 0.03825). There were no significant differences in the fEPSP slope between Veh *Bdnf* KO slices (5.85 ± 0.178) and LiCl treated *Bdnf* KO (5.899 ± 0.1703). (Two-way ANOVA Interaction F~1,29~ = 3.24 p=0.08, Row (Genotype) F~1,29~ = 5.09 \*p=0.032, Column (Diet) F~1,29~ = 12.61 \*p=0.001. Sidak's multiple comparisons Veh CTL vs LiCl CTL \*p=0.029, Veh *Bdnf* KO vs LiCl *Bdnf* KO p=0.999, Veh CTL vs Veh *Bdnf* KO p=0.739, LiCl CTL vs LiCl *Bdnf* KO \*p=0.007 n = 6--10 recordings per group).**DOI:** [http://dx.doi.org/10.7554/eLife.25480.004](10.7554/eLife.25480.004)

To investigate whether BDNF was required for lithium's antimanic-like effects, we used the amphetamine hyperlocomotor test in which lithium blunts the increased locomotor activity that occurs following acute amphetamine injection, a commonly used assay for the antimanic-like effects of lithium in mice ([@bib23]; [@bib28]). The amphetamine induced hyperlocomotor test was performed subsequent to the FST in the same cohorts of mice. Littermate CTL mice treated with acute amphetamine have the expected significant increase in the total number of horizontal beam breaks compared to vehicle treated mice ([Figure 2B](#fig2){ref-type="fig"}). CTL mice receiving lithium treatment showed a small non-significant increase in the total number of beam breaks compared to vehicle treated CTL mice, and were indistinguishable from chronic lithium treated mice receiving acute amphetamine, indicating that lithium treatment could prevent the hyperactivity induced by amphetamine ([Figure 2B](#fig2){ref-type="fig"}). In contrast, while inducible *Bdnf* KO mice receiving acute amphetamine showed a significant increase in the number of beam breaks compared to vehicle treated *Bdnf* KOs, and a slight increase with chronic lithium treatment, the chronic lithium treated *Bdnf* KO mice receiving acute amphetamine still had a significant increase in the number of beam breaks comparable to amphetamine treatment alone. These data demonstrate that lithium treatment does not block the hyperlocomotor effects of amphetamine in inducible *Bdnf* KO mice and thus suggests that BDNF is required for the antimanic-like effect of lithium.

We next assessed whether the loss of BDNF impacted lithium's effect on synaptic efficacy from hippocampal slices. Inducible *Bdnf* KO and littermate control mice were given lithium treated chow or untreated chow ([Figure 1A](#fig1){ref-type="fig"}). The slope of the input/output (I/O) curve, which was plotted as the presynaptic volley versus the fEPSC slope, was taken as a measure of synaptic efficacy associated with synaptic density or strength of individual synapse. We found that in CTL mice, chronic lithium treatment resulted in a significant reduction in the slope of the I/O curve in hippocampal slices in comparison to mice not treated with lithium ([Figure 2C](#fig2){ref-type="fig"}), indicating that chronic lithium treatment reduces hippocampal synaptic strength. Inducible *Bdnf* KO mice that did not receive lithium had a similar slope of the I/O curve compared to untreated littermate CTL mice ([Figure 2C](#fig2){ref-type="fig"}) showing that the loss of BDNF did not impact synaptic efficacy. We also found that the slope of the I/O curve in the hippocampal slices from the inducible *Bdnf* KO mice treated with lithium was also unchanged in comparison to the untreated CTL and *Bdnf* KO mice ([Figure 2C](#fig2){ref-type="fig"}), suggesting that BDNF expression is required for the lithium-mediated reduction of synaptic strength.

BDNF and TrkB are required for lithium-mediated decreases in AMPAR mEPSC amplitudes {#s2-3}
-----------------------------------------------------------------------------------

Previous work has shown that lithium treatment produces a significant decrease in AMPAR miniature excitatory postsynaptic current (mEPSC) amplitudes in cultured neurons, which has been suggested to underlie the antimanic effects of lithium ([@bib4]; [@bib14]; [@bib72]). We therefore incubated dissociated C57BL/6 hippocampal neurons with 1 mM LiCl or 1 mM NaCl, to control for changes in osmolarity, for 11--15 days and then recorded AMPAR mEPSCs ([Figure 3A](#fig3){ref-type="fig"}). Lithium treatment resulted in a significant decrease in AMPAR mEPSC amplitudes in comparison to NaCl treated or untreated CTL neurons ([Figure 3B--D](#fig3){ref-type="fig"}). To examine whether lithium's effect on AMPAR mEPSC amplitudes was due to synaptic scaling, we plotted in rank order the amplitudes from each condition with a linear fit equation. We found that lithium treatment resulted in a 41% and 26% decrease in the slope compared to untreated and NaCl treatment, respectively ([Figure 3E](#fig3){ref-type="fig"}). These data show lithium produces a downward scaling of all AMPAR mEPSC amplitudes and impacts post-synaptic homeostatic plasticity. Notably, lithium did not produce generalized effects on synaptic measures as there were no changes in mEPSC frequency compared to untreated or NaCl treated neurons ([Figure 3F](#fig3){ref-type="fig"}). Since lithium's effects on AMPAR mEPSC amplitudes were due to synaptic scaling, which can be influenced by AMPAR trafficking, we examined the surface expression of the AMPAR subunit, GluA1. We performed surface biotinylation experiments and found lithium treatment results in a significant decrease in GluA1 surface expression relative to total GluA1 in comparison to untreated or NaCl treated neurons ([Figure 3G](#fig3){ref-type="fig"}).10.7554/eLife.25480.005Figure 3.Chronic lithium treatment causes a significant decrease in synaptic scaling and surface GluA1 expression.(**A**) Timeline for treatment of dissociated hippocampal neurons with LiCl and NaCl. (**B**) Example traces of AMPAR mEPSCs from CTL untreated (top), 1 mM NaCl treated (middle) and 1 mM LiCl treated (bottom) dissociated hippocampal neurons. (**C**) Chronic LiCl treatment of cultured hippocampal neurons caused a trend towards decreased AMPA mEPSC average amplitudes in comparison to CTL neurons. Chronic NaCl treatment did not cause a change in average AMPA mEPSC amplitude in comparison to CTL neurons (ANOVA F~2,39~ = 2.597 p*=*0.0873, Bonferroni's multiple comparisons CTL vs NaCl p\>0.999, CTL vs LiCl p=0.091). (**D**) Cumulative probability histogram showing a significant leftward shift (decrease) in the amplitudes of AMPAR-mEPSCs from cells chronically treated with 1 mM LiCl in comparison to CTL untreated and 1 mM NaCl treated neurons (Kolmogorov-Smirnov test: CTL vs 1 mM \>LiCl \*p=1.75×10^−43^, *D* = 0.234, 1 mM NaCl vs 1 mM LiCl \*p=8.14×10^−27^, *D* = 0.167, *n*= 12--18 recordings per condition). (**E**) Rank order plot of CTL untreated AMPAR mEPSC amplitudes vs 1 mM LiCl AMPAR mEPSC amplitudes revealed a 41% decrease. Rank order plot of 1 mM NaCl AMPAR mEPSC amplitudes vs 1 mM LiCl AMPAR mEPSC amplitudes showed a 26% decrease. (CTL vs LiCl line of best fit y = 0.59x, CTL vs NaCl line of best fit y = 0.85x, Difference between NaCl and LiCl. 26, *n*= 12--18 recordings per condition). (**F**) AMPAR-mEPSC frequency is indistinguishable between CTL untreated, NaCl treated, and LiCl treated neurons (ANOVA F~4,57~ = 0.129 p=0.97, *n* = 12--18 recordings). (**G**) Surface biotinylation experiments revealed that chronic lithium treatment of hippocampal neurons results in a significant decrease in the surface/total GluA1 ratio (ANOVA F~2,21~ = 2.911 p=0.0766, Dunnett's multiple comparisons CTL vs NaCl p=0.58, CTL vs LiCl \*p=0.04, *n*= 3 separate experiments).**DOI:** [http://dx.doi.org/10.7554/eLife.25480.005](10.7554/eLife.25480.005)

Since our data demonstrated that BDNF was required for lithium's antimanic-like effects in mice and lithium-mediated decrease in synaptic strength, we examined whether chronic lithium treatment's effects on synaptic function, which may ultimately trigger the behavioral effects, were dependent on BDNF and its high affinity receptor TrkB. BDNF is a secreted protein that has been shown to influence synaptic upscaling and downscaling, depending on the brain region examined ([@bib40]; [@bib59]; [@bib61]). We therefore examined whether lithium's effects on AMPAR mEPSC amplitudes were dependent on BDNF. We cultured hippocampal neurons from *Bdnf ^fl/fl^* mice and infected them with lentivirus expressing Cre recombinase (Cre) tagged with GFP to delete the gene of interest or GFP alone as a control. Previous studies from our laboratory have shown that this lentivirus construct expressing Cre tagged with GFP can efficiently knock out endogenous gene expression without triggering cell death ([@bib2]; [@bib51]). As expected, GFP infected neurons treated with chronic lithium had a significant decrease in AMPAR mEPSC amplitudes in comparison to untreated or NaCl treated neurons ([Figure 4A--D](#fig4){ref-type="fig"}). In BDNF deficient cultures, *Bdnf^fl/fl^* neurons infected with Cre, there was no difference in AMPAR mEPSC amplitudes compared to GFP infected neurons suggesting loss of BDNF does not impact this synaptic measure ([Figure 4A--D](#fig4){ref-type="fig"}). In contrast to wild-type neurons, we found chronic lithium treatment of BDNF deficient cultures induced a small but nonsignificant decrease in AMPAR mEPSC amplitudes ([Figure 4D](#fig4){ref-type="fig"}) suggesting a requirement for BDNF. We also examined mEPSC frequency from these six treatment groups and did not find a significant change with any condition (data not shown). Taken together, these data suggest that chronic lithium's effect on AMPAR mEPSC amplitudes is dependent on BDNF.10.7554/eLife.25480.006Figure 4.BDNF is required for the lithium-mediated decrease in AMPAR mEPSC amplitude.(**A**) Example traces from GFP infected *Bdnf ^fl/fl^* neurons with no treatment (CTL, top) or 11--17 day incubation with 1 mM NaCl (middle) or 1 mM LiCl (bottom). (**B**) Example traces from Cre infected *Bdnf ^fl/fl^* neurons with no treatment (control, top) or 11--17 day incubation with 1 mM NaCl (middle) or 1 mM LiCl (bottom). (**C**) Cumulative probability histogram showing a significant leftward shift (decrease) in AMPAR mEPSC amplitudes between *Bdnf ^fl/fl^* -GFP control untreated and *Bdnf ^fl/fl^* -GFP LiCl conditions. There is also a significant leftward shift (decrease) between *Bdnf ^fl/fl^* -GFP LiCl and *Bdnf ^fl/fl^* -Cre LiCl conditions (Kolmogorov-Smirnov test: GFP Control vs GFP LiCl p\<0.0001 *D* = 0.309, GFP LiCl vs Cre LiCl \*p\<0.0001 *D* = 0.19, *n* = 10--13 recordings per condition). (**D**) Lithium caused a significant decrease in AMPAR mEPSC amplitudes in *Bdnf ^fl/fl^* -GFP neurons compared to control *Bdnf ^fl/fl^* -GFP neurons. However, lithium did not impact AMPAR mEPSC amplitudes between *Bdnf ^fl/fl^* -Cre neurons in comparison to untreated control *Bdnf ^fl/fl^* -Cre neurons (ANOVA F~5,59~ = 5.694 \*p=0.0002, Tukey's multiple comparisons GFP Control vs GFP LiCl \*p=0.003, Cre Control vs Cre LiCl p=0.197, *n* = 10--13 recordings per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.25480.006](10.7554/eLife.25480.006)

To further evaluate whether BDNF signaling is required for lithium's effects on AMPAR mediated synaptic transmission, we explored the requirement for the TrkB receptor. We cultured hippocampal neurons from *Ntrk2 ^fl/fl^* mice and infected them with either lentivirus expressing Cre or GFP. Consistent with our previous results, GFP infected neurons treated with lithium had a significant decrease in AMPAR mEPSC amplitude compared to untreated or NaCl treated neurons ([Figure 5A--D](#fig5){ref-type="fig"}). We found *Ntrk2 ^fl/fl^* neurons infected with CreGFP, had indistinguishable AMPAR mEPSC amplitudes compared to GFP infected neurons demonstrating that loss of TrkB does not affect this synaptic measure ([Figure 5D](#fig5){ref-type="fig"}). In agreement with data from the *Bdnf* deficient neurons, we found lithium treatment of *Ntrk2* deficient neurons did not affect AMPAR mEPSC amplitudes showing a requirement for TrkB in lithium's effect on AMPAR mEPSC responses ([Figure 5D](#fig5){ref-type="fig"}). We measured mEPSC frequency in the six treatment groups and did not observe any significant differences demonstrating a specific effect of lithium on mEPSC properties (data not shown).10.7554/eLife.25480.007Figure 5.Lithium-mediated decrease in AMPAR mEPSC amplitude is dependent on TrkB.(**A**) Example traces from GFP infected *Ntrk2 ^fl/fl^* neurons, untreated Control (top), 1 mM NaCl treatment (middle), and 1 mM LiCl treatment (bottom). (**B**) Examples from Cre infected *Ntrk2 ^fl/fl^* neurons, untreated Control (top), 1 mM NaCl treatment (middle) and 1 mM LiCl treatment (bottom). (**C**) Cumulative probability histogram showing a significant leftward shift (decrease) in AMPAR-mEPSC amplitudes from *Ntrk2 ^fl/fl^* -GFP neurons treated with 1 mM LiCl. (Kolmogorov-Smirnov test: GFP control vs GFP LiCl \*p\<0.0001, *D* = 0.181, GFP LiCl vs Cre LiCl \*p\<0.0001, *D* = 0.153, *n* = 9--17 recordings per condition). (**D**) Lithium caused a significant decrease in AMPAR-mEPSC amplitudes in *Ntrk2 ^fl/fl^* -GFP neurons compared to untreated control *Ntrk2 ^fl/fl^* -GFP neurons. However, lithium was unable to cause any significant changes in AMPAR-mEPSCs in *Ntrk2 ^fl/fl^* -Cre neurons compared to untreated *Ntrk2 ^fl/fl^* -Cre control (ANOVA F~5,76~ = 5.107 \*p=0.0004, Bonferonni multiple comparison test: GFP control vs GFP LiCl \*p=0.002, Cre Control vs Cre LiCl p\>0.999, *n* = 9--17 recordings per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.25480.007](10.7554/eLife.25480.007)

Dynamin-dependent endocytosis is required for lithium-mediated decrease in AMPAR mEPSC amplitudes {#s2-4}
-------------------------------------------------------------------------------------------------

Our data so far shows that chronic lithium treatment of hippocampal neurons leads to a significant decrease in AMPAR mEPSC amplitudes that is dependent on BDNF-TrkB signaling. The decrease in AMPAR mEPSC amplitudes and the reduced GluA1 surface membrane expression suggests lithium is augmenting AMPAR endocytosis. Therefore, we examined whether inhibiting AMPAR endocytosis would rescue the synaptic phenotype observed with lithium treatment. AMPAR endocytosis is dependent on the GTPase dynamin ([@bib41]), which is expressed by three related genes in mammals ([@bib57]). Dynamin 1 and 3 (*Dnm1* and *Dnm3*) are highly expressed in neurons and found in dendrites ([@bib9]; [@bib52]). Previous work has shown that constitutive *Dnm1^−/−^*/ *Dnm3^−/−^* double KO mice are not viable ([@bib57]). Therefore, to examine the contribution of both dynamin1 and dynamin3 on lithium mediated synaptic effects, we crossed *Dnm1 ^fl/fl^* mice with *Dnm3^−/−^* mice as the constitutive deletion of *Dnm3* does not impact synaptic function ([@bib57]). We cultured *Dnm1 ^fl/fl^* / *Dnm3^−/−^* neurons and infected them with lentivirus expressing Cre to delete *Dnm1* and thus generate the double KOs, or GFP as a control. The GFP infected neurons treated with lithium had a significant reduction in AMPAR mEPSC amplitudes compared to untreated neurons showing that the loss of *Dnm3* does not impact the effect of lithium on synaptic function ([Figure 6A--C](#fig6){ref-type="fig"}). In contrast, deletion of both *Dnm1* and *Dnm3* occluded the effect of chronic lithium treatment on AMPAR mEPSC amplitudes in comparison to untreated cultures demonstrating that lithium is potentiating dynamin dependent endocytosis of AMPAR ([Figure 6C](#fig6){ref-type="fig"}).10.7554/eLife.25480.008Figure 6.Dynamin-dependent endocytosis is required for lithium-mediated decrease in AMPAR-mEPSC amplitudes.(**A**) Example traces from GFP infected *Dnm1 ^fl/fl^*/*Dnm3^−/−^* neurons, control (top), chronic NaCl treatment (1 mM, middle) and chronic LiCl treatment (1 mM, bottom). (**B**) Example traces from Cre infected *Dnm1 ^fl/fl^*/*Dnm3^−/−^* neurons, control (top), chronic NaCl treatment (1 mM, middle), and chronic LiCl treatment (1 mM, bottom). (**C**) Chronic lithium treatment caused a significant decrease in AMPAR mEPSC amplitude in *Dnm1 ^fl/fl^*/*Dnm3^−/−^* neurons infected with lenti-GFP virus compared to untreated *Dnm1 ^fl/fl^*/*Dnm3^−/−^* neurons. However, there was no significant difference in AMPAR-mEPSC amplitudes between untreated and lithium treated *Dnm1 ^fl/fl^*/*Dnm3^−/−^* neurons infected with lenti-CreGFP virus (ANOVA F~5,68~ = 5.048 \*p=0.0006, Bonferonni multiple comparison test: GFP control vs GFP LiCl \*p=0.02, Cre Control vs Cre LiCl p=0.455, *n* = 8--12 recordings per condition). (**D**) Example traces from wildtype neurons recorded with DMSO-internal solution, control (top), chronic NaCl treatment (1 mM, middle), and chronic LiCl treatment (1 mM, bottom). (**E**) Example traces from wildtype neurons recorded with Dyngo-internal solution, control (top), chronic NaCl treatment (1 mM, middle), and chronic LiCl treatment (1 mM, bottom). (**F**) In comparison to control untreated neurons, chronic lithium treatment caused a significant decrease in AMPAR-mEPSC amplitudes. In contrast, lithium did not cause a significant change in AMPAR-mEPSC amplitudes in comparison to the untreated control when Dyngo is included in the internal pipette solution (ANOVA F~5,69~ = 6.985, \*p\<0.0001, Bonferonni multiple comparison test: DMSO control vs DMSO LiCl \*p\<0.0001, Dyngo Control vs Dyngo LiCl p\>0.999, *n* = 11--17 recordings per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.25480.008](10.7554/eLife.25480.008)

To control for possible compensatory effects due to the loss of *Dnm1* and *Dnm3*, in our next experiments we cultured hippocampal neurons from C57BL/6 mice and acutely inhibited dynamin activity in the postsynaptic neuron. We chronically treated neurons with lithium and then added the pan-dynamin inhibitor Dyngo ([@bib45]), or the vehicle 1% DMSO, to the internal pipette solution prior to our recordings. Consistent with previous data, chronic lithium treatment resulted in a significant decrease in AMPAR mEPSC amplitudes in neurons recorded with vehicle in the pipette solution ([Figure 6D--F](#fig6){ref-type="fig"}). In contrast, the presence of Dyngo in the pipette solution rescued the decrease in AMPAR mEPSC amplitudes seen after lithium treatment ([Figure 6F](#fig6){ref-type="fig"}). Taken together, these experiments demonstrate that chronic lithium treatment enhances AMPAR endocytosis to alter synaptic function in a dynamin dependent manner and the loss of dynamin, specifically *Dnm1* and *Dnm3*, can rescue the synaptic deficits.

Discussion {#s3}
==========

In the current study, we report that lithium requires BDNF-TrkB signaling to mediate its antimanic as well as synaptic effects. Chronic lithium treatment in vivo results in a sustained increase in BDNF mRNA and protein expression. However, while BDNF is required for the antimanic effects of lithium it is not required for the antidepressant effects. We determined that chronic lithium treatment in vivo caused a significant decrease in I/O curves from hippocampal slices that were dependent on BDNF expression. We investigated the effect of chronic lithium on synaptic function and found a significant synaptic downscaling of AMPAR mEPSC amplitudes that was dependent on BDNF as well as its high affinity receptor, TrkB. The decrease in AMPAR mEPSC amplitudes was due to a decrease in postsynaptic surface expression of GluA1 driven by dynamin-dependent AMPAR endocytosis, which could be acutely countered by administration of a dynamin inhibitor. Collectively, these data demonstrate that lithium can target AMPA receptor endocytosis to alter synaptic function.

In these experiments we used lithium treated chow to administer the drug to mice to more closely mimic the oral administration used by patients with bipolar disorder. In initial experiments, we established a chronic lithium regimen that resulted in clinically relevant lithium levels in serum. In each experiment we confirmed that an animal had a serum lithium level of 0.5--3.0 mM/L to ensure that the molecular and behavioral studies were performed under conditions similar to long-term treatment for Bipolar Disorder. We show that chronic lithium treatment in rodents causes a sustained increase in BDNF mRNA and protein in the hippocampus. However, BDNF was not required for the antidepressant action of lithium. Previous studies have shown that BDNF is required for the antidepressant effects of traditional antidepressants ([@bib1]; [@bib48]), as well as rapid antidepressant effects of ketamine ([@bib6]). While the current data showing lithium can exert an antidepressant effect in inducible *Bdnf* KOs is unexpected, the finding could be due to several possibilities. First, these data may suggest that mood stabilizers mediate an antidepressant response in a manner distinct from conventional antidepressants that target the monoamine system and independent of BDNF. Second, previous work with traditional antidepressants has largely focused on changes in *Bdnf* mRNA, with changes in BDNF protein not as fully explored leaving it unclear the time frame that conventional antidepressants increase BDNF protein ([@bib18]). The rapid antidepressant action of ketamine requires BDNF and is protein translation dependent, with BDNF protein rapidly increased but then returning to baseline ([@bib6]). In contrast, data from the current study shows that lithium treatment results in a sustained increase in *Bdnf* mRNA and protein expression. Taken together, these may data suggest acute manipulation of BDNF protein expression is involved in rapid antidepressant effects while a more chronic increase in BDNF expression is required for antimanic effects.

Lithium produces significant effects on synaptic transmission that may underlie its antimanic properties. Previous work has consistently shown that lithium application significantly decreases AMPAR mEPSC amplitudes in cultured neurons ([@bib4]; [@bib16]; [@bib29]; [@bib63]; [@bib72]). We replicated these data and showed chronic lithium treatment of hippocampal neurons results in a significant decrease in AMPA mEPSC amplitudes compared to control conditions. We also found that lithium treatment did not alter AMPA mEPSC frequency demonstrating specificity to the impact of the drug on synaptic transmission. Further analysis revealed that lithium produced a significant downward multiplicative synaptic scaling of all AMPAR-mEPSC amplitudes consistent with an impact on post-synaptic homeostatic plasticity. Previous in vivo and in vitro studies have shown that lithium decreases GluA1 and GluA2 surface expression in the hippocampus and in cultured cortical neurons ([@bib15], [@bib14]; [@bib72]). In addition, we found that in vivo lithium treatment caused a significant decrease in I/O curves in hippocampal slices, which is reminiscent of the decreased AMPA/NMDA ratio previously seen in rats following chronic lithium treatment ([@bib14]). Lithium treatment has also been shown to decrease phosphorylation of Thr840 on GluA1, which is associated with decreased AMPAR signaling ([@bib66]). In the current study, we found that lithium treatment of hippocampal neurons elicits synaptic downscaling due to decreased GluA1 surface expression demonstrating a previously unknown effect of lithium on post-synaptic homeostatic plasticity.

The lithium triggered significant decrease on AMPAR mEPSC amplitudes and hippocampal I/O curves was occluded in neurons lacking *Bdnf* suggesting a requirement in lithium's action. To confirm these data, we examined neurons with a deletion of *Ntrk2* and found that lithium's effect on AMPAR-mEPSC amplitudes was also occluded. While these data demonstrate that the effect of lithium on AMPA mEPSC amplitudes is dependent on BDNF and TrkB, the requirement for TrkB was more robust than BDNF per se. These findings may be due to low level expression of BDNF remaining after viral infection of Cre recombinase that acts on TrkB receptors or alternatively some minor effects of neurotrophin 3 (NT3) or neurotrophin 4 (NT4) activating the TrkB receptor to impact lithium's effects on synaptic transmission. Regardless, these results demonstrate a rather unexpected requirement for BDNF-TrkB signaling in lithium mediated effects on synaptic scaling as increased BDNF expression is typically associated with increased AMPAR surface expression ([@bib33]; [@bib50]; [@bib53]). However, there is precedent for BDNF to induce downscaling of AMPAR surface expression. Specifically, acute increases in BDNF have been shown to increase GluA1 and GluA2 surface expression, whereas chronic increases in BDNF decrease surface expression of GluA1 and GluA2 ([@bib59]). Collectively, these data suggest that chronic lithium treatment through a sustained increase in BDNF expression leads to synaptic downscaling.

The BDNF-TrkB dependence of lithium-mediated effects on mEPSC amplitudes was due to decreased surface expression of GluA1, suggesting the removal of AMPARs by endocytosis. In neuronal synapses, dynamin has been shown to be a key mediator of endocytosis. To determine whether lithium promotes AMPAR endocytosis by a dynamin-dependent mechanism, we utilized a genetic approach with deletion of *Dnm1* and *Dnm3* and reversed the lithium-mediated decrease in AMPAR mEPSC amplitudes. To further establish that lithium triggers AMPAR endocytosis, we treated individual cells acutely with the dynamin inhibitor, Dyngo and demonstrated that lithium's impact on AMPAR endocytosis can be rapidly countered by dynamin inhibition. Previous work has shown that AMPAR internalization/endocytic membrane trafficking of the postsynaptic neuron can be regulated in a dynamin-dependent process to control strength ([@bib41]). Taken together, our data show that lithium regulates dynamin-dependent endocytosis and rapidly removes AMPAR from the postsynaptic membrane altering synaptic efficacy.

Altered glutamatergic signaling and hyperactivity have been implicated in the pathology of bipolar disorder. Mania in bipolar patients has been associated with elevated glutamate signaling ([@bib38]; [@bib54]). In post-mortem brain tissue of individuals with bipolar disorder an increase in expression of the vesicular glutamate transporter (VGlut1) mRNA and glutamate have been observed ([@bib19]; [@bib30]). Human induced pluripotent stem cell (IPSC) derived neurons from patients with bipolar disorder were shown to have lower action potential thresholds, increased evoked and spontaneous action potentials, and larger action potential amplitudes suggesting they are hyperactive in comparison to neurons derived from healthy controls ([@bib46]). Conversely, lithium treatment has been shown to reverse the glutamatergic hyperactivity from IPSC derived neurons from patients with bipolar disorder ([@bib46]). In addition, recent work has suggested that lithium may alter neuronal activity by regulating G-protein gated inward rectifier K+ (GIRK) channels ([@bib20]), which may modulate homeostatic scaling of AMPAR responses. Although, we cannot exclude lithium-mediated regulation of neuronal activity as a component of our observations, a parsimonious interpretation of our results suggests that direct biochemical effects of lithium mediated signaling is the key driver for the AMPAR downscaling we observed. Our findings showing that lithium triggers dynamin-dependent endocytosis of AMPARs may be a way in which to counteract the increased glutamatergic signaling associated with mania. Further work will be necessary to pursue this hypothesis and explore the role of lithium on dynamin-dependent endocytosis as a potential mechanism in antimanic action.

Findings from the current study identify a critical role for BDNF in the antimanic and synaptic effects of lithium treatment. These results demonstrate that lithium specifically impacts excitatory neurotransmission by decreasing AMPAR-mEPSCs through dynamin-dependent endocytosis to reduce surface expression of AMPAR subunits. These data start to provide a framework to elucidate the mechanisms underlying lithium's effect on synaptic transmission which may offer insight into novel therapeutic targets for the treatment of bipolar disorder.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

Male C57BL/6 mice aged 6--8 weeks were habituated to the animal facilities for at least 7 days prior to behavior testing. The mice were maintained on a 12 hr light/dark cycle with *ad libitum* access to food and water, unless otherwise noted for lithium treatment groups. The *Bdnf^fl/fl^* and *Ntrk2 ^fl/fl^* mice were generated as previously described and maintained as homozygous crosses ([@bib42]; [@bib60]). The inducible *Bdnf* knockout (KO) mice were generated as previously described ([@bib48]). The *Dnm1 ^fl/fl^* and the *Dnm3^−/−^* null KO mice were generated as previously described ([@bib21]; [@bib57]). All behavioral testing was done with age and weight matched male mice that were balanced by genotype. In these experiments we utilized only male mice as previous work from our laboratory has shown that loss of BDNF can impact depression-related behaviors in a sex-dependent manner ([@bib5]). All electrophysiology and biochemistry experiments utilized male and female mice. All experiments were performed and data analyzed by an experimenter blind to drug condition and genotype. Animal protocols were approved by the Institutional Care and Use Committee at UT Southwestern Medical Center.

Lithium treatment in vivo {#s4-2}
-------------------------

The lithium treatment consisted of mice given 0.2% lithium chloride (LiCl) chow (Harlan Teklad, East Millstone, NJ) for 4 days and then switched to 0.4% LiCl (Harlan Teklad) chow for the remainder of the study, which lasted from 11 to 17 days total. All mice received water as well as a bottle of 0.9% sodium chloride (NaCl) to control for ion imbalances known to occur with lithium administration. Control mice were kept on identical chow except it did not contain lithium.

Measurement of lithium in serum {#s4-3}
-------------------------------

Trunk blood was collected from all animals after the completion of the lithium treatment and behavioral testing. Whole blood was kept on ice until it was spun at 3000 RPM at 4°C for 10 min to separate red blood cells and serum. Lithium ion counts were made using a flame photometer (Jenway PFP7) and concentration was calculated following the construction of a standard curve. Mice with serum lithium concentrations below 0.5 mM and above 3 mM were excluded from behavioral and biochemical analyses.

Behavior {#s4-4}
--------

### Forced swim test {#s4-4-1}

The forced swim test (FST) was performed in accordance with published protocols ([@bib27]). In brief, mice were placed in a glass 4 L beaker with 3 L of 23 ± 2°C water for 6 min and test session were video-recorded. The last 5 min of each trial were scored by an observer blinded to drug condition and genotype to determine immobility time.

### Locomotor activity {#s4-4-2}

Mice were habituated to the testing room for 1 hr and then given an intraperitoneal (i.p.) injection of amphetamine hydrochloride (Sigma, St. Louis, MO) at 2 mg/kg dissolved in saline or saline as a control. Mice were then immediately placed in standard home cages under red light and locomotor activity was measured for 2 hr by photocell beams linked to computer acquisition software (San Diego Instruments, San Diego, CA). The total beam counts for the 2 hr period were collected as a measurement of amphetamine induced hyperactivity ([@bib74]).

Hippocampal slice preparation and field potential electrophysiology {#s4-5}
-------------------------------------------------------------------

Mice chronically treated with lithium (11--17 days) were anesthetized with isoflurane before decapitation. The brain was removed and immersed for 2--3 min in ice-cold dissection buffer containing the following (in mM): 2.6 KCl, 1.25 NaH~2~PO~4~, 26 NaHCO~3~, 0.5 CaCl~2~, 5 MgCl~2~, 212 sucrose and 10 glucose. The hippocampus was dissected out and cut with a vibratome into 400-μm-thick transverse sections in ice-cold dissection buffer continuously supplied with 95% O~2~ and 5% CO~2~. Area CA3 was surgically removed from each slice immediately after sectioning. The sections recovered in oxygenated ACSF containing the following (in mM): 124 NaCl, 5KCl, 1.25 NaH~2~PO~4~, 26 NaHCO~3~, 2 CaCl~2~, 2 MgCl~2~ and 10 glucose, pH 7.4 (continuously equilibrated with 95% O~2~ and 5% CO~2~) for 2--3 hr at 30°C. Hippocampal slices were transferred to the recording chamber and perfused with ACSF at a rate of 2--3 ml/min at 30°C. Field EPSPs (fEPSPs) were evoked by inserting a bipolar platinum-tungsten stimulating electrode (Frederick Haer, Bowdoin, ME) into Schaffer collateral/commissural afferents. The extracellular recording electrodes filled with ACSF (resistance, 1--2 MΩ) were placed into the CA1 just beneath the molecular layer. Baseline responses were collected every 30 s using an input stimulus intensity that induced 30--40% of the maximum response. After a 20 min stable baseline, an ascending series of stimulus input intensities (range, 5 to 200 μA) were applied and the input/output (I/O) curve was plotted by the slope of fEPSP versus afferent volley amplitude. Data are presented as mean ± SEM and analyzed using two-way ANOVA. Sidak's multiple comparisons test were conducted after significant interaction effects were found. A p value of \<0.05 was required for statistical significance.

Cell culture {#s4-6}
------------

Dissociated hippocampal cultures were prepared as previously described ([@bib35]; [@bib58]). Whole hippocampi were dissected from postnatal day 0--3 (P0-P3) mice. The hippocampi were trypsinized (\~10 mg/mL trypsin; Invitrogen), dissociated mechanically, and plated on Matrigel (Corning Biosciences, Tewksbury, MA)-coated coverslips for electrophysiology or directly onto tissue culture treated plates for protein collection for western blot analysis. At 1 d in vitro (DIV), 4 µM cytosine arabinoside (ARAC; Sigma) was added. At 4 DIV, the ARAC concentration was decreased to 2 µM with a media change. Treatment with LiCl (1 mM) solution (Sigma) or NaCl (1 mM) solution (Sigma) was initiated at 4 DIV and lasted for 11--17 days. The *Bdnf^fl/fl^*, *Ntrk2 ^fl/fl^*, and *Dnm1 ^fl/fl^* / *Dnm3^−/−^* cultures were infected with lentivirus expressing Cre recombinase (Cre) tagged with GFP or lentivirus expressing GFP alone as a control at 4 DIV. Lentivirus constructs and virus preparation from HEK293T/17 cells were prepared as previously described ([@bib2]). HEK293T/17 cell line was purchased from ATCC (Cat. Number: CRL-11268). All electrophysiology experiments and protein collected for western blot analysis were done on 15--21 DIV cultures.

Patch-clamp electrophysiology {#s4-7}
-----------------------------

Whole-cell patch clamp recordings were performed on hippocampal pyramidal neurons as previously described ([@bib27]). The external Tyrode's solution contained (in mM): 150 NaCl, 4 KCl, 2 CaCl~2~, 1.25 MgCl~2,~ 10 glucose, and 10 Hepes (ph 7.4) at \~300 mOsm. The pipette internal solution contained (in mM): 110 K-gluconate, 20 KCl, 10 NaCl, 10 Hepes, 0.6 EGTA, 4 Mg-ATP, 0.3 Na-GTP, and 10 lidocaine *N*-ethyl bromide (pH 7.3) at \~300 mOsm. Pipettes had a resistance between 3--7 MΩ. The junction potential between the internal and external solutions was \~12 mV and was subtracted from all recordings. AMPAR-mediated mEPSCs were recorded in the presence of 50 µM (2R)-amino-5-phosphonovaleric acid (AP5; Tocris, Bristol, UK), 1 µM tetrodotoxin (TTX; EMD Millipore, Billerica, MA), and 50 µM picrotoxin (PTX; Sigma). For the acute dynamin inhibitor studies, dynamin activity was inhibited in the postsynaptic neuron by adding 30 µM Dyngo-4A (Abcam, Cambridge, MA) to the internal pipette solution ([@bib45]). DMSO was added to the internal pipette solution as a control for these experiments. Data were acquired using a MultiClamp 700B amplifier and Clampex 10.0 software (Molecular Devices, Sunnyvale, CA). Recordings were sampled at 100 µs, filtered at 2 kHz with a gain of 5. No more than three recordings were obtained per coverslip. AMPAR-mEPSCs were analyzed from a 3--5 min recording using MiniAnalysis software by an experimenter blind to drug condition and genotype.

Quantitative RT-PCR {#s4-8}
-------------------

Briefly, fresh frozen hippocampi were dissected and total RNA was extracted using Trizol (Invitrogen) following the manufacturer's instruction. Conditions for cDNA synthesis, amplification, and primer sequences were previously described ([@bib1]).

Protein quantification {#s4-9}
----------------------

Anterior hippocampal slices (\~1 mm thick, 2--3 per mouse) were dissected and flash-frozen following 11 days of lithium treatment or immediately following the last behavioral test depending on the experiment. Hippocampal tissue was lysed in a radio immunoprecipitation assay (RIPA) buffer containing: 50 mM Tris pH 7.4, 1% Igepal, 0.1% SDS, 0.5% Na deoxycholate, 4 mM EDTA, 150 mM NaCl, phosphatase inhibitors (10 mM Na pyrophosphate, 50 mM NaF, 2 mM Na orthovanadate), and protease inhibitors (cOmplete Mini tablets, Roche, Basel, Switzerland). Protein concentration was quantified with the Quick-Start Bradford assay (Bio-Rad, Hercules, CA). Approximately 30 µg of protein was electrophoresed on SDS-PAGE gels and then transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies overnight at the following dilutions: BDNF (Abcam, Cat. Number: ab108319; RRID: [AB_10862052](https://scicrunch.org/resolver/AB_10862052)), 1:1000, GAPDH (Cell Signaling, Cat. Number: 2118S; RRID: [AB_561053](https://scicrunch.org/resolver/AB_561053)) 1:50,000, phosphorylated GSK3β (Ser9, Cell Signaling, Cat. Number: 9323S) and total GSK3β (Cell Signaling, Cat. Number: 9315S) 1:30,000. Primary antibodies for phospho-GSK3β included 5% BSA. After washing, the membranes were incubated in anti-rabbit secondary antibodies: BDNF, 1:5000, GAPDH, 1:10,000, phospho-GSK3β and total GSK3β, 1:10,000. Protein bands were detected using ECL then exposed to film. Following development of phospho-GSK3β, membranes were stripped using Restore PLUS Western Blot Stripping Buffer (ThermoScientific, Waltham, MA), put in block, and then in primary antibody for total GSK3β. BDNF expression was normalized to GAPDH while a ratio of phospho- GSK3β intensity to total GSK3β was examined. The phospho-GSK3β and total GSK3β antibodies are known to recognize doublet bands (Cell Signaling).

Cell surface AMPAR expression measurement {#s4-10}
-----------------------------------------

Membrane biotinylation experiments were performed as previously described ([@bib53]). Dissociated hippocampal cultures from C57BL/6 mice were incubated in Tyrode's solution containing 1 mg/ml sulfo-NHS-LC-biotin (Pierce/Thermofisher) for 20 min on ice. The biotin reactions were quenched by incubating the cultures in Tris-buffered saline (TBS) with 15 mM ammonium chloride for 5 min on ice, and then washed twice with TBS for 5 min on ice. Following the second TBS wash, the cultures were lysed in RIPA buffer (as described above) for 10 min on ice and spun at 12,000 rpm for 5 min to remove non-solubilized material. Total protein concentration was quantified by Quik-Start Bradford assay (Bio-rad). 100 µg of protein from each sample was incubated with 100 µL of washed UltraLink NeutrAvidin (Pierce/Thermofisher) immobilized beads and rotated overnight at 4°C. Beads were washed with three times with RIPA buffer, followed by three washes with TBS at 4°C. Protein was eluted from the beads with SDS-PAGE sample buffer supplemented with β-mercaptaethanol (BME) for 10 min at 95°C. Eluted surface protein and 20 µg of total protein in SDS-PAGE-BME sample buffer were resolved by 10% SDS-PAGE gel, transferred to nitrocellulose, and probed with anti-GluA1 antibody (1:1000, Chemicon/EMD Millipore, Cat. Number: MAB2263) and anti-GAPDH antibody (1:50,000) overnight. Secondary anti-rabbit antibodies were at 1:2000 and 1:10,000 for GluA1 and GAPDH respectively. Surface GluA1 over total GluA1 ratio is reported.

Statistics {#s4-11}
----------

Data are reported as mean ± SEM. Statistical differences in the FST, locomotor tests, western blot, QPCR, mEPSC amplitude and frequency were assessed using unpaired two-tailed Student's *t* test or one-way ANOVA when appropriate. Tukey and Bonferroni *post hoc* tests were used when appropriate. Differences in the cumulative probability histograms were assessed with Kolmogorov-Smirnov test. Statistical significance was defined at p≤0.05. Statistical outliers were identified with the Robust regression and Outlier removal (ROUT) method. All t-test, ANOVAs, associated post hoc tests, and ROUT method statistical tests were performed with Prism 6 (GraphPad, La Jolla, California). The Kolmogorov-Smirnov test was performed using Past 3.02 (<http://folk.uio.no/ohammer/past/>).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Lu Chen (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission

Summary:

This is a relatively straightforward but highly significant study demonstrating that chronic lithium administration to mice reduces amphetamine-induced locomotion (a model for anti-manic effects) through a mechanism that depends on BDNF-TrkB signaling, whereas lithium\'s ability to reduce immobility in the forced swim test (a model for anti-depressant effects) does not depend on BDNF. It is particularly compelling that both tests were conducted in the same cohort of mice. Furthermore, patch-clamp recordings showed that lithium reduced AMPAR-mediated mEPSC amplitude in cultured hippocampal neurons in a manner reminiscent of homeostatic downscaling, and that this effect also required BDNF-TrkB pathway. The decrease in AMPAR-mediated mEPSC amplitude in cultured hippocampal neurons was associated with reduced surface expression of GluA1 subunits. Two different strategies for inhibiting dynamin-dependent endocytosis rescued the lithium-induced decrease in mEPSC amplitude. These are novel findings that will be of broad interest. Experiments are well designed and the effects are convincing.

Here are some suggestions for the authors to consider in order to strengthen their findings and clarify the conclusions:

Essential revisions:

1\) It remains unclear what is the signal triggering mEPSC downscaling. Does lithium trigger an acute increase in spontaneous neuronal activity probably through inhibition of GIRK channels (Farhy Tselnicker et al., 2014)? If so, it would justify the \'homeostatic\' nature of a negative feedback response through the proposed postsynaptic downscaling.

2\) The authors should provide further insight into the downstream signaling mechanisms that lead to down-regulation of mEPSC amplitude by lithium. In particular, it is important to better understand whether inhibition of GSK-3beta is involved in BDNF-induced synaptic downscaling by lithium. It can be tested by using specific inhibitors of GSK-3beta and examining if they occlude lithium-induced synaptic downscaling. As Akt can be activated by numerous growth factors, including BDNF, it may down-regulate synaptic AMPARs by inhibiting GSK3beta.

3\) All recordings are done in cultured neurons. Although others have apparently shown that in vivo lithium exposure reduces mEPSC amplitude (three studies are cited), were those recordings done in hippocampal neurons and under conditions similar to those studied here (e.g., lithium dosing? age of animal?). If not, it would be important to use slice physiology to confirm in the current mouse model that lithium reduces mEPSC amplitude and perhaps show that this is absent in slices from BDNF knockout mice.

4\) Is a reduction in amphetamine-induced locomotor activity an accepted model for lithium\'s anti-manic effects? Even if so, the authors should be a little more conservative in referring to lithium\'s action in this test as \"anti-manic\".

10.7554/eLife.25480.010

Author response

*Essential revisions:*

*1) It remains unclear what is the signal triggering mEPSC downscaling. Does lithium trigger an acute increase in spontaneous neuronal activity probably through inhibition of GIRK channels (Farhy Tselnicker et al., 2014)? If so, it would justify the \'homeostatic\' nature of a negative feedback response through the proposed postsynaptic downscaling.*

We thank the reviewer for this suggestion. We conducted additional experiments to test this premise (i.e. lithium triggering an acute increase in activity) and, if anything, in our system, we detect an acute decrease in activity (the frequency of spontaneous action potential firing in the absence of lithium 0.96 ± 0.27 Hz and the presence of lithium 0.22 ± 0.06 Hz in external solution) which is not consistent with the downscaling we observed. While, we cannot exclude lithium-mediated regulation of neuronal activity as a component of our observations, a parsimonious interpretation of our results suggest that direct biochemical effects of lithium mediated signaling is the key driver for the downscaling. We now include this point in the Discussion.

*2) The authors should provide further insight into the downstream signaling mechanisms that lead to down-regulation of mEPSC amplitude by lithium. In particular, it is important to better understand whether inhibition of GSK-3beta is involved in BDNF-induced synaptic downscaling by lithium. It can be tested by using specific inhibitors of GSK-3beta and examining if they occlude lithium-induced synaptic downscaling. As Akt can be activated by numerous growth factors, including BDNF, it may down-regulate synaptic AMPARs by inhibiting GSK3beta.*

To address this comment we have performed additional experiments in which we examined an acute 24-hour treatment of the GSK-3beta inhibitor SB216763 on C57BL/6 hippocampal neurons and did not observe an effect on mEPSC amplitude (DMSO Control: 16.06 ± 1.346 S.E.M. vs SB21673: 16 ± 1.178 S.E.M., *n*=10-12 recordings per condition). The lack of an effect of the GSK-3beta inhibitor on mEPSC amplitudes may be due to the acute nature of the treatment, therefore we chronically treated C57Bl/6 hippocampal neurons with SB216763 for 11-15 days as was done with lithium chloride in our previous experiments. However, chronic SB216763 treatment compromised the survival of cultured neurons, which made the interpretation of these experiments difficult.

*3) All recordings are done in cultured neurons. Although others have apparently shown that in vivo lithium exposure reduces mEPSC amplitude (three studies are cited), were those recordings done in hippocampal neurons and under conditions similar to those studied here (e.g., lithium dosing? age of animal?). If not, it would be important to use slice physiology to confirm in the current mouse model that lithium reduces mEPSC amplitude and perhaps show that this is absent in slices from BDNF knockout mice.*

We have followed the reviewers' advice and tested the chronic in vivo impact of lithium on the CA3-CA1 synapses recorded from hippocampal slices. In this setting, we could detect a clear decrease in input/output curves obtained from animals chronically treated with lithium ([Figure 2C](#fig2){ref-type="fig"}). Moreover, this decrease in input/output slope was not detected in mice lacking BDNF ([Figure 2C](#fig2){ref-type="fig"}). We have also modified the text to make it more apparent that the previous studies showing lithium exposure reduces mEPSC amplitude were performed on hippocampal neurons in culture.

*4) Is a reduction in amphetamine-induced locomotor activity an accepted model for lithium\'s anti-manic effects? Even if so, the authors should be a little more conservative in referring to lithium\'s action in this test as \"anti-manic\".*

The amphetamine hyperactivity test is the most commonly used test assessing 'anti-manic effects' in rodents. Therefore, we used similar language in our original submission. Nevertheless, we agree with the reviewer regarding caution in interpreting lithium's effects as anti-manic in rodent models. In the revised manuscript we have tried to dampen the interpretation of the in vivo behavioral data and now refer to lithium's behavioral action as 'antimanic-like' in the study.

[^1]: Department of Molecular Neurobiology, Max Planck Institute for Experimental Medicine, Goettingen, Germany.
